NL-OMON33962招募中不适用
Erythrocytapheresis versus Phlebotomy as maintenance therapy in patients with hereditairy hemochromatosis; a randomised, single blinded, sequential, cross-over trial - Erythrocytapheresis versus Phlebotomy in HH patients
Sanquin Bloedbank0 个研究点目标入组 48 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients with ironoverload, homozygous for C282Y, treated with Phlebotomy as maintenance therapy for at least 6 month
- •Demonstrated therapy compliance with prescribed P so far
- •Ferritin level between 30-50 ug/L at start of the inclusion
- •Age 18 years an older
- •Weight > 50 kg
- •Signed informed consent
- •Willigness to fill out additional questionnaires at three points in time
排除标准
- •Patients recieving others therapies such as chelating therapy or forced dietary regimen
- •Patients younger than 18 years
- •Patients with excessive overweight ( BMI>35)
- •Patients which are mentally incapacitade
- •Women being pregnant or expecting/planning to become pregnant during the two years period of the study
- •Patients with a malignancy
- •HH patients which are current blood donors
研究者
相似试验
已完成
3 期
Haemochromatosis:Phlebotomy Versus Erythrocytapheresis TherapyHemochromatosisNCT00202436Sanquin Research & Blood Bank Divisions40
招募中
不适用
efficacy of erythrocyte transfusion in mortality rate of patients with aluminum phosphideIRCT20180428039443N1Tehran University of Medical Sciences140
Unknown
3 期
Erythrocytapheresis Versus Phlebotomy as Maintenance Therapy in Hereditary Hemochromatosis (HH) PatientsHereditary HemochromatosisNCT01398644Sanquin Research & Blood Bank Divisions40
已完成
2 期
eukocytapheresis for Maintenance of Remission in Patients with Refractory Inflammatory Bowel Disease: A single-centre, Randomized, Double Blinded Triallcerative ColitisJPRN-UMIN000004242Department of Lower Gastroenterology, Hyogo College of Medicine30
已完成
不适用
Ex Vivo Expanded Erythroblast-Transplantation for patient with critical limb ischemiaPeripheral Arterial Disease (PAD) , Buerger disease, and arteritis associated with collagen diseases (Fontaines stage: III and IV)JPRN-UMIN000021374EVEETA Study Group11